IPO Databook: Propanc Biopharma (PPCB US) - Oct 2026

126 Views19 Jul 2026 10:05

SUMMARY

Propanc Biopharma, Inc. is a development-stage healthcare company developing new cancer treatments, with its lead product PRP involving pro-enzymes. This filing registers shares for resale.
The company focuses on new cancer treatments, with its lead candidate PRP receiving FDA Orphan Drug Designation and holding 85 patents.
The company reported total assets of $12,799,912 as of June 30, 2026, but faces substantial doubt about its ability to continue as a going concern.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream